Ductal carcinoma in situ of the breast

Annual Review of Medicine

Volumn 51, Issue , 2000, Pages 17-32

  Silverstein, Melvin J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Breast cancer; DCIS; Ductal carcinoma in situ; In situ breast cancer; Minimal breast cancer; Noninvasive breast cancer

Indexed keywords

TAMOXIFEN;

BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER RECURRENCE; CANCER SURVIVAL; CANCER THERAPY; CARCINOMA IN SITU; DEEP VEIN THROMBOSIS; FEMALE; HUMAN; INTRADUCTAL CARCINOMA; LUNG EMBOLISM; MAMMOGRAPHY; MASTECTOMY; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REVIEW; UNITED STATES; UTERUS CANCER;

AXILLA; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 0034101763     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.51.1.17     Document Type: Review

References (42)

1. 1. Nemoto T, Varia J, Bedwani RN, et al. 1980. Management and survival of female breast cancer: results of a national survey by The American College of Surgeons. Cancer 45:2917-24
2. 2. Ernster VL, Barclay J, Kerlikowske K, et al. 1996. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA 275:913-18
3. 3. Landis SH, Murray T, Bolden S, Wingo PA. 1999. Cancer statistics, 1999. CA Cancer J. Clin. 49:8-31
4. 4. Schwartz GF, Lagios MD, Carter D, et al. 1997. Consensus conference on the classification of ductal carcinoma in situ. Cancer 80:1798-1802
5. 5. Aasmundstad TA, Haugen OA. 1992. DNA ploidy in intraductal breast carcinomas. Eur. J. Cancer 26:956-59
6. 6. Meyer J. Cell kinetics of histologie variants of in situ breast carcinoma. 1986. Breast Cancer Res. Treat. 7:171-80
7. 7. Barnes DM, Meyer JS, Gonzalez JG, et al. 1991. Relationship between c-erbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ. Breast Cancer Res. Treat. 18:11-17
8. 8. Bartkova J, Barnes DM, Millis RR, et al. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. 1990. Hum. Pathol. 21:1164-67
9. 9. Lagios NM, Margolin FR, Westdahl PR, et al. 1989. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 63:619-24
10. 10. Schwartz GF. 1994. The role of excision and surveillance alone in subclinical DCIS of the breast. Oncology 8(2):21-26
11. 11. Silverstein MJ, Poller DN, Waisman JR, et al. 1995. Prognostic classification of breast ductal carcinoma in situ. Lancet 345:1154-57
12. 11a. Silverstein MJ. 1998. Ductal carcinoma in situ of the breast: controversial issues. Oncologist 3:94-103
13. 12. Silverstein MJ, Lagios MD, Craig PH, et al. 1996. A prognostic index for ductal carcinoma in situ of the breast. Cancer 77:2267-74
14. 13. Dickson RB, Lippman ME. 1995. Growth factors in breast cancer. Endocr. Rev. 16(5):559-89
15. 14. Lippman ME. 1993. The rational development of biological therapies for breast cancer. Science 259:631-32
16. 15. Fisher B, Costantino J, Redmond C, et al. 1993. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N. Engl. J. Med. 328:1581-86
17. 15a. Fisher B, Dignam J, Wolmark H, et al. 1999. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial. Lancet 353:1993-2000
18. 16. Rosner D, Bedwani RN, Vana JB, et al. 1980. Noninvasive breast carcinoma. Results of a national survey of The American College of Surgeons. Ann. Surg. 192:139-47
19. 17. Ashikari R, Hadju SI, Robbins GF. 1971. Intraductal carcinoma of the breast. Cancer 28:1182-87
20. 18. Fisher ER, Constantino J, Fisher B, et al. 1995. Pathologic finding from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17: intraductal carcinoma (ductal carcinoma in situ). Cancer 75:1310-19
21. 19. Fisher B, Dignam J, Wolmark N, et al. 1998. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from the National Surgical Adjuvant Breast and Bowel Project B-17. J. Clin. Oncol. 16:441-52
22. 20. Deleted in proof
23. 21. Fisher B, Costantino JP, Wickerham DL, et al. 1998. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90:1371-88
24. 22. Wolmark N. Tamoxifen after surgery/RT decreases local recurrence risk in DCIS patients. 1999. Oncol. News Int. 8(2):12 (Suppl. 2)
25. 23. Julien J, Bijker N, Sylvester R, et al. 1998. The role of radiotherapy in breast conserving treatment of ductal carcinoma in situ (DCIS): first results of EORTC trial 10853. Eur. J. Cancer 34:S8 (Suppl.)
26. 24. Recht A. 1997. Side effects of radiation therapy. See Ref. 24a, pp. 347-352
27. 24a. Silverstein MJ, ed. 1997. Ductal Carcinoma in Situ of the Breast. Baltimore, MD: Williams & Wilkins
28. 25. Page DL, Dupont WD, Rogers LW, et al. 1995. Continued local recurrence of carcinoma 15-25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy. Cancer 76:1197-1200
29. 26. Silverstein MJ. Van Nuys Prognostic Index for DCIS. 1997. See Ref. 24a, pp. 491-504
30. 27. Solin LJ, Yet I-T, Kurtz J, et al. 1993. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Correlation of pathologic parameters with outcome of treatment. Cancer 71:2532-42
31. 28. Bellamy COC, McDonald C, Salter DM, et al. 1993. Noninvasive ductal carcinoma of the breast. The relevance of histologic categorization. Hum. Pathol. 24:16-23
32. 29. Silverstein MJ. 1998. Prognostic factors and local recurrence in patient with ductal carcinoma in situ of the breast. Breast J. 4:349-62
33. 30. Silverstein MJ, Lagios MD, Groshen S, et al. 1999. The influence of margin width on local control in patients with ductal carcinoma in situ (DCIS) of the breast. N. Engl. J. Med. 340:1455-61
34. 31. Hansen N, Giuliano A. 1997. Axillary dissection for ductal carcinoma in situ. See Ref. 24a, pp. 577-84
35. 32. Silverstein MJ, Rosser RJ, Gierson ED, et al. 1987. Axillary dissection for intraductal breast carcinoma - is it indicated? Cancer 59:1819-24
36. 33. Krag DN, Weaver DL, Alex JC, et al. 1993. Surgical resection and radiolocalization of sentinel lymph node in breast cancer using a gamma probe. Surg. Oncol. 2:335-40
37. 34. Giuliano AE, Dale PS, Turner RR, et al. 1995. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann. Surg. 222:394-401
38. 35. Albertini JJ, Lyman GH, Cox C, et al. 1996. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 276:1818-22
39. 36. Silverstein MJ, Barth A, Poller DN, et al. 1995. Ten-year results comparing mastectomy to excision and radiation therapy for ductal carcinoma in situ of the breast. Eur. J. Cancer 31:1425-27
40. 37. Silverstein MJ, Lagios MD, Martino S, et al. 1998. Outcome after local recurrence in patients with ductal carcinoma in situ of the breast. J. Clin. Oncol. 16:1367-73
41. 38. Solin LJ, Fourquet A, McCormick B, et al. 1994. Salvage treatment for local recurrence following breast conserving surgery and definitive irradiation for ductal carcinoma in situ (intraductal carcinoma) of the breast. Int. J. Radiat. Oncol. Biol. Phys. 30:3-9
42. 39. Solin LJ, Kurtz J, Fourquet A, et al. 1996. Fifteen year results of breast conserving surgery and definitive breast irradiation for treatment of ductal carcinoma in situ of the breast. J Clin. Oncol. 14:754-63